@article{Wei_J-2021_39410,
title = {Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom},
author = {Wei, J. and Stoesser, N. and Matthews, P. and Ayoubkhani, D. and Studley, R. and Bell, I. and Bell, J. and Newton, J. and Farrar, J. and Diamond, I. and Rourke, E. and Howarth, A. and Marsden, B. and Hoosdally, S. and Jones, E. and Stuart, D. and Crook, D. and Peto, T. and Pouwels, K. and Eyre, D. and Walker, A. and Lambert, A. and Thomas, T. and Black, R. and Felton, A. and Crees, M. and Jones, J. and Lloyd, L. and Sutherland, E. and Pritchard, E. and Vihta, K. and Doherty, G. and Kavanagh, J. and Chau, K. and Hatch, S. and Ebner, D. and Ferreira, L. and Christott, T. and Dejnirattisai, W. and Mongkolsapaya, J. and Cameron, S. and Tamblin-Hopper, P. and Wolna, M. and Brown, R. and Cornall, R. and Screaton, G. and Lythgoe, K. and Bonsall, D. and Golubchik, T. and Fryer, H. and Cox, S. and Paddon, K. and James, T. and House, T. and Robotham, J. and Birrell, P. and Jordan, H. and Sheppard, T. and Athey, G. and Moody, D. and Curry, L. and Brereton, P. and Jarvis, I. and Godsmark, A. and Morris, G. and Mallick, B. and Eeles, P. and Hay, J. and VanSteenhouse, H. and Lee, J.},
month = {sep},
year = {2021},
abstract = {We report that in a cohort of 45,965 adults, who were receiving either the ChAdOx1 or the BNT162b2 SARS-CoV-2 vaccines, in those who had no prior infection with SARS-CoV-2, seroconversion rates and quantitative antibody levels after a single dose were lower in older individuals, especially in those aged &gt;60 years. Two vaccine doses achieved high responses across all ages. Antibody levels increased more slowly and to lower levels with a single dose of ChAdOx1 compared with a single dose of BNT162b2, but waned following a single dose of BNT162b2 in older individuals. In descriptive latent class models, we identified four responder subgroups, including a ‘low responder’ group that more commonly consisted of people aged &gt;75 years, males and individuals with long-term health conditions. Given our findings, we propose that available vaccines should be prioritized for those not previously infected and that second doses should be prioritized for individuals aged &gt;60 years. Further data are needed to better understand the extent to which quantitative antibody responses are associated with vaccine-mediated protection.},
pages = {1140-1149},
volume = {6},
issue = {9},
journal = {Nature Microbiology},
publisher = {Springer Nature},
url = {https://doi.org/10.1038/s41564-021-00947-3},
}
